Skip to main content

Table 2 Anti-PD-L1 antibody alone or in combination with other treatments in RCC patients

From: Clinical potential of PD-1/PD-L1 blockade therapy for renal cell carcinoma (RCC): a rapidly evolving strategy

Agents

Phase

Participants

Dose

Outcome

Refs.

Atezolizumab Bevacizumab

2

305

1200 mg

15 mg/kg

Improved PFS, which had no association with tumor mutation and neoantigen burden

[179]

Atezolizumab Bevacizumab

3

915

1200 mg

15 mg/kg

Improved PFS versus sunitinib (11·2 months versus 7.7 months) with a favorable safety profile

[175]

Atezolizumab

Cabozantinib

1b

102

1200 mg

40–60 mg

Prolonged PFS to19.5 months

[226]

Atezolizumab Bevacizumab

2

59

1200 mg

15 mg/kg

Improved PFS (8.7 moths) with detection of TRAEs in 83% of patients

[227]

Atezolizumab Interferon-α

1b

158

1200 mg

180 μg

Significant ORR (20.0%)

[184]

Atezolizumab

1

17

0.01–20 mg/kg

Improved OS (28.9 months) and PFS (5.6 months)

[177]

Atezolizumab

Navoximod

1

157

50–1000 mg

Acceptable safety, tolerability, and pharmacokinetics

[228]

Avelumab

Axitinib

3

886

10 mg/kg

5 mg

Prolonged PFS and OS versus sunitinib which was in association with below-median NLR

[199, 229]

Atezolizumab

A2AR antagonist

1

68

840 mg

50–100 mg

A durable clinical benefit associated with increased CTLs infiltration into the tumor

[230]

  1. Note: Programmed cell death ligand 1 (PD-L1), Renal cell carcinoma (RCC), Overall survival (OS), Objective response rate (ORR), Progression-free survival (PFS), Adenosine A2A receptor (A2AR), Treatment-related adverse events (TRAEs), Neutrophil–lymphocyte ratio (NLR), Cytotoxic T cells (CTLs)